{"name":"FibroBiologics","slug":"fibrobiologics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":7407000,"netIncome":-18646000,"cash":4894000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tolerogenic Fibroblasts","genericName":"Tolerogenic Fibroblasts","slug":"tolerogenic-fibroblasts","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Tolerogenic Fibroblasts","genericName":"Tolerogenic Fibroblasts","slug":"tolerogenic-fibroblasts","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE4tUUR6bm1LdWJfSV9rbzJQMWp5cTBDMTZjZFNBdnpJWnJCaWV5U3FfdFI2dnQ1X0JObU9xNERIZEJ6Z2xKSEM3ZHBuVDFRSW1VU2xybmhvMWV3NEdNTWfSAWNBVV95cUxQSUVHS2tsMjl6REswQUxjTzJEUktuTEhyTkhMeV9teFFQS01LNGg5cWJTRWtRNkRoNEI5S0xwRHQ2QWhsRlpmcTRSQ0lycVBQM2RLWFhVaDV6ZmVlcTE2bVl0a0U?oc=5","date":"2026-03-30","type":"pipeline","source":"Bitget","summary":"FibroBiologics Plunges 27% Intraday: What’s Behind the Sharp Decline? - Bitget","headline":"FibroBiologics Plunges 27% Intraday: What’s Behind the Sharp Decline?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9taUZyc0NlZjNYbEJJd2Q2dVdwTmxzeVNWNnVQaXgxQlVKckpZdGlyYXoxWHMtMTF5bWh0a05uaGdPVjFyc2FXZ1EyNWxaalNEVk9DOG9IVXc3a1ZZbDE4TkxobUdoM252TENQT1BR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Fibrobiologics (FBLG) - Stock Titan","headline":"If You Invested $1,000 in Fibrobiologics (FBLG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQVUJ0d1JhR0R0Wl9TZHFLWDhET1dhNDRRVGJZWUk4Q1NLMVYwUXRjRnpGbTRFZW9wLWRDaFBtYzdKRm8takFuOEI4WlllZ2lDT3NuSHc4SWtkbGFCSk1XMXppNUNCMkxfMTlmcmppcnIxYWk5cFNWNGZRWnI1V2VPaUVPSU8wZENtaHFtU3EwSWxxY25SZ0l3RGFuTTlnUnkxNkF0ckk1dnVicDdkV2c?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"FibroBiologics (NASDAQ: FBLG) adds 2025 governance, pay and ownership details - Stock Titan","headline":"FibroBiologics (NASDAQ: FBLG) adds 2025 governance, pay and ownership details","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOWdDY0E0cFpXS3RDV25pdHBpVzJmU3l4ZlBTR2FsaDNvR2NxaGZ4a3NVMEowQVJjWEktemx4czktaXRPYzRmejJtenU3NG1XY2lDZXJDeWxmUEpNZHMyVkJKcDlFUTBFSDBTNVl1SlNYeFhQRTVmTEpPX2oyck9nZUNfRk9hWFJGTlNacHFDLXhxb0pLMVRsLTNad09jTFV0eWdYUHQ1X01IeDJRZGVTTDItVFViWWdwNUxN?oc=5","date":"2026-03-05","type":"trial","source":"Stock Titan","summary":"Fibroblast therapy moves toward Phase 1/2 trial for diabetic foot ulcers - Stock Titan","headline":"Fibroblast therapy moves toward Phase 1/2 trial for diabetic foot ulcers","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORGZtaWlmQXdsY1F0VlBmVHc4R1NDRjhFelVuaG9BNXQ5SXlSRFE3XzVva2w3eEtMV1owMnFpUzAtTVptdkdsUTNMcGZGY1ZsM0NDMmJuR2pIaEFiaEs4U3BkUHVvMlcxYkxPN3BWd05rNzdMR3pWS1JSc1o2WU1kOFJ2eEYteUJHTzRadVdxY1ZLVThmeFE?oc=5","date":"2026-01-07","type":"pipeline","source":"Stock Titan","summary":"How a little-known biotech uses fibroblast cells against chronic disease - Stock Titan","headline":"How a little-known biotech uses fibroblast cells against chronic disease","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA2Uk13b1hTV2FRT2c2WUdYV0hrT1dabld5WDZVV0M5SzNSZWZEbE5MUDl5Q0lNbXlheFFDcjYwa09BU0xJaWRSMTgzQzNWYkpueno3OEpjTjRJMGRFaERkc1AxWENhTlQ0?oc=5","date":"2025-09-11","type":"regulatory","source":"MarketBeat","summary":"FibroBiologics (FBLG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FBLG - MarketBeat","headline":"FibroBiologics (FBLG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FBLG","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBoOENzNGZMQ3hRbG9xYzlxbWxxNmlVZ2JkYXZMakIxRVhxc3pxQTlFWEJRM2NFeUdmU2tlclQ0ckVfWTRTM09Bc3VPTFVONUI4UGZldXdMVTVNdDE3bzJJWkVSQ3V5c1piV1I2eEpOUnZHZ0ls?oc=5","date":"2025-02-26","type":"pipeline","source":"Pharmaceutical Executive","summary":"Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologics - Pharmaceutical Executive","headline":"Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNQ0Nibkp1MnNGdkQwdnpnMVNrSTQzWFJqQUNZQk9HbkJuZGdHSGs3a2RnWjFLVThocnNSdnFNQ3FIbXlPcEJETnN3eUs2akJGWE9kemdKaVNJLU5hYjNDcVJXVEtGalIyems0VVFpdWcyTkI4dnBCR09CdkZIYlBwTzdCOVkweHBlNGxtLWtwaw?oc=5","date":"2024-10-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"FibroBiologics, Charles River agree on therapies manufacture - Pharmaceutical Technology","headline":"FibroBiologics, Charles River agree on therapies manufacture","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7407000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-18646000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4894000,"cashHistory":[],"totalAssets":9619000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}